Imugene
- Short interest
- 0.31%
- −0.03 pp 30d
- as of 9 Oct 2026
- Reported shorts
- 1.7M
- Shares on issue
- 548.902M
Imugene (IMU) Short Interest
Imugene (ASX:IMU) had 0.31% of shares reported as short positions as of 9 Oct 2026, representing 1,718,026 shares. Imugene operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Imugene
Imugene is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. Their pipeline includes B-cell immunotherapies and oncolytic virotherapy technologies designed to activate the immune system against cancer cells. Imugene aims to improve the lives of cancer patients by creating more effective and tolerable treatments.
Company profile →Imugene (ASX:IMU) has 0.31% of its shares on issue reported as short positions as of 9 Oct 2026, or about 1,718,026 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 1.20 percentage points. Its highest recorded short interest was 8.10% in August 2023. IMU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads IMU today
- Zanger BreakoutNot a candidate
- CAN SLIMNot a candidate
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 15rank 987 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
IMU fundamentals
In the year to 30 Jun 2026, Imugene (ASX:IMU) recorded a net loss after tax of A$105.3M. A year earlier it recorded a net loss after tax of A$69.0M. Return on equity −84.5% (FY). Figures are in AUD, the company's reporting currency; source: Company filing (extracted) and Yahoo Finance, as at 12 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest IMU news
All news- Application for quotation of securities - IMU
asx · 13 Oct 2026
- Notice of Annual General Meeting/Proxy Form
asx · 8 Oct 2026
- Dr John Le Gall appointed Chief Medical Officer
asx · 6 Oct 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss IMU
Start a research thread or post the first pulse update